$OGEN On the watch-list for a substantial move higher .

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oragenics Inc (OGEN) today and set a price target of $2. The company’s shares closed yesterday at $0.55, close to its 52-week low of $0.38.
Selvaraju observed:
“We believe the Phase 2 study could report top-line results in early 2020. If AG013 could significantly reduce the duration and lower the incidence of 2 data may serve as one of the two pivotal data sets required to support regulatory filing, in our view. AG013 has been granted Fast Track designation in the U.S. and Orphan Drug status in Europe. In the wake of this update, we reiterate our Buy rating and $2 price target. Preclinical data of lantibiotics published. Lantibiotics have been developed to possess both strong antimicrobial properties as well as the ability to evade common resistance mechanisms. Last week, preclinical data of the company’s lantibiotic compound, OG253, were published in Toxicology and Applied Pharmacology.”

ANALYSTS RATING BUY
ANALYSTS PRICE TARGET $2.50

COMPANY PROFILE
OGEN IS focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation. The collaborations allows Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.